Key Points
- Chidozie Ugwumba sold 4,278 shares of CLNN on April 1 at an average price of $4.97 for $21,261.66, reducing his stake to 426,816 shares (a 0.99% ownership decrease).
- The April 1 sale continues a pattern of sustained insider disposals since late January, including multiple sizeable sales (e.g., 15,284 shares on Jan. 29 and several 4k–12k share transactions) by the major shareholder.
- Clene is a small‑cap biotech (market cap ≈ $60.3M) that recently missed quarterly EPS expectations and faces negative forecasted EPS, yet analysts maintain a consensus Moderate Buy with an average target of $32.60, underscoring a disconnect between insider selling and Wall Street optimism.
Clene Inc. (NASDAQ:CLNN - Get Free Report) major shareholder Chidozie Ugwumba sold 4,278 shares of the firm's stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $4.97, for a total transaction of $21,261.66. Following the transaction, the insider directly owned 426,816 shares in the company, valued at $2,121,275.52. This represents a 0.99% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Major shareholders that own at least 10% of a company's stock are required to disclose their transactions with the SEC.
Chidozie Ugwumba also recently made the following trade(s):
- On Tuesday, February 3rd, Chidozie Ugwumba sold 5,559 shares of Clene stock. The shares were sold at an average price of $4.10, for a total value of $22,791.90.
- On Monday, February 2nd, Chidozie Ugwumba sold 3,800 shares of Clene stock. The stock was sold at an average price of $4.04, for a total value of $15,352.00.
- On Friday, January 30th, Chidozie Ugwumba sold 5,686 shares of Clene stock. The stock was sold at an average price of $4.13, for a total value of $23,483.18.
- On Thursday, January 29th, Chidozie Ugwumba sold 15,284 shares of Clene stock. The shares were sold at an average price of $4.32, for a total value of $66,026.88.
- On Wednesday, January 28th, Chidozie Ugwumba sold 8,717 shares of Clene stock. The stock was sold at an average price of $4.91, for a total transaction of $42,800.47.
- On Tuesday, January 27th, Chidozie Ugwumba sold 4,139 shares of Clene stock. The shares were sold at an average price of $5.08, for a total transaction of $21,026.12.
- On Monday, January 26th, Chidozie Ugwumba sold 6,418 shares of Clene stock. The stock was sold at an average price of $5.02, for a total transaction of $32,218.36.
- On Friday, January 23rd, Chidozie Ugwumba sold 5,556 shares of Clene stock. The stock was sold at an average price of $5.27, for a total transaction of $29,280.12.
- On Thursday, January 22nd, Chidozie Ugwumba sold 12,665 shares of Clene stock. The shares were sold at an average price of $5.32, for a total transaction of $67,377.80.
- On Wednesday, January 21st, Chidozie Ugwumba sold 12,119 shares of Clene stock. The shares were sold at an average price of $5.05, for a total value of $61,200.95.
Clene Stock Performance
Shares of CLNN opened at $5.12 on Friday. Clene Inc. has a 52-week low of $2.28 and a 52-week high of $13.50. The firm has a market cap of $60.31 million, a price-to-earnings ratio of -1.97 and a beta of 0.62. The business's fifty day moving average is $4.99 and its 200-day moving average is $6.66.
Clene (NASDAQ:CLNN - Get Free Report) last released its quarterly earnings data on Thursday, March 12th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.74) by ($0.14). The company had revenue of $0.08 million during the quarter, compared to analyst estimates of $0.03 million. As a group, research analysts forecast that Clene Inc. will post -5.19 EPS for the current fiscal year.
Hedge Funds Weigh In On Clene
A number of institutional investors and hedge funds have recently modified their holdings of CLNN. Jones Financial Companies Lllp bought a new stake in Clene in the third quarter valued at $29,000. Jane Street Group LLC acquired a new position in Clene during the 2nd quarter worth approximately $47,000. State Street Corp boosted its holdings in Clene by 138.4% in the fourth quarter. State Street Corp now owns 29,801 shares of the company's stock worth $175,000 after acquiring an additional 17,300 shares in the last quarter. PEAK6 LLC bought a new stake in shares of Clene during the fourth quarter valued at approximately $294,000. Finally, Lunt Capital Management Inc. lifted its holdings in shares of Clene by 2.5% in the 3rd quarter. Lunt Capital Management Inc. now owns 52,260 shares of the company's stock worth $315,000 after purchasing an additional 1,250 shares in the last quarter. 23.28% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
A number of analysts have weighed in on the stock. Weiss Ratings restated a "sell (d-)" rating on shares of Clene in a research report on Friday, January 9th. D. Boral Capital reissued a "buy" rating and set a $23.00 price target on shares of Clene in a research note on Thursday, March 12th. Canaccord Genuity Group reiterated a "buy" rating and set a $48.00 target price on shares of Clene in a research report on Friday, March 13th. Finally, Benchmark reaffirmed a "buy" rating on shares of Clene in a research note on Thursday, December 4th. Six analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $32.60.
Check Out Our Latest Stock Report on Clene
About Clene
(
Get Free Report)
Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company's flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene's platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.
Clene's lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson's disease, and multiple sclerosis (MS).
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
